Porous microsphere composite carnotoxin gel and preparation method thereof

By using spray drying and cross-linked hyaluronic acid in a gel loaded with porous microspheres, the problems of uneven distribution of botulinum toxin and complex preparation process are solved, and the uniform sustained release and stability of botulinum toxin are achieved Improved, suitable for a variety of medical and cosmetic applications.

CN118986858AInactive Publication Date: 2024-11-22YIRUI BIOTECHNOLOGY (SUZHOU) CO LTD

Patent Information

Application Number
CN202411131452.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-18
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Botox distribution in existing porous microsphere compound botulinum preparations is uneven, which affects the drug's sustained release effect, is complex in preparation process and is cost-effective, and is insufficient in biocompatibility and stability.

Method used

Polylevulate-hydroxyapatite microspheres were prepared by spray-drying method, polylevulate-hydroxyapatite microspheres were prepared, combined with cross-linked hyaluronic acid and buffer solution, and lyophilized protective agent and ultrasonic treatment were used, and cross-drying was added. Coupling agent and thickening agent to form a stable porous microsphere composite botulinum gel.

Benefits of technology

It achieves uniform distribution and sustained release of botulinum toxin, extends the drug action time, improves stability and biocompatibility, reduces preparation costs, and is suitable for various medical and cosmetic needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986858A_ABST
    Figure CN118986858A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, and discloses a gel of porous microsphere composite meat toxin and a preparation method thereof, and the gel comprises the following components by weight: 5-15 parts of porous microspheres; 0.1 to 1 part of carnotoxin; 70 to 90 parts of a gel matrix; 5-10 parts of a buffer solution; 0.5 to 2 parts of a cross-linking agent; 0.5 to 1.5 parts of a thickening agent; and 0.5-2 parts of a stabilizer. The slow-release effect of the meat toxin is achieved by loading the meat toxin through the porous microspheres, the meat toxin can be slowly released within a long time through the structural design of the porous microspheres, the action time of the medicine is prolonged, the requirement for frequent injection is reduced, the meat toxin is treated by using a freeze-drying protective agent, and the meat toxin is compounded with the porous microspheres, so that the slow-release effect of the meat toxin is achieved. The biological activity of the kreotoxin is effectively protected, the stability of the kreotoxin is further improved through ultrasonic treatment and cross-linking reaction in the preparation process, and the effectiveness of the kreotoxin in the storage and use process is ensured.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, in particular to a porous microsphere composite botulinum toxin gel and a preparation method thereof. Background Art

[0003] In the field of modern medicine and cosmetology, botulinum toxin type A is widely used in facial beauty and treatment of muscle spasms because of its ability to effectively block nerve conduction. However, traditional botulinum toxin preparations have some limitations, such as short duration of action, frequent injections, and discomfort and poor compliance in patients. In addition, the stability of botulinum toxin also limits its application in storage and transportation. In order to solve these problems, in recent years, researchers have begun to focus on combining botulinum toxin with porous microspheres to achieve sustained release and stabilization of botulinum toxin. Porous microspheres have become an ideal drug carrier due to their high specific surface area and good biocompatibility. Polylactic acid-glycolic acid copolymer and hydroxyapatite (porous microspheres) are two commonly used porous microsphere materials with biodegradability and controllable degradation rate. The release rate of the drug can be controlled by adjusting its composition and preparation process. As the main component of human bones, hydroxyapatite has excellent biocompatibility.

[0004] However, there are still some shortcomings in the porous microsphere composite botulinum toxin preparations currently on the market. First, the distribution of botulinum toxin is uneven during the composite process, which affects the sustained release effect of the drug. Secondly, the existing preparation process is relatively complicated and costly, which is not conducive to large-scale production. Finally, the biocompatibility and stability of the composite product still need to be improved. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a porous microsphere-compounded botulinum toxin gel and a preparation method thereof, which solves the problem of uneven distribution of botulinum toxin during the compounding process, affecting the sustained-release effect of the drug.

[0006] To achieve the above objectives, the present invention is implemented through the following technical scheme: a porous microsphere composite botulinum toxin gel, comprising the following components in parts by weight: porous microspheres: 5-15 parts; botulinum toxin: 0.1-1 parts; gel matrix: 70-90 parts; buffer solution: 5-10 parts; cross-linking agent: 0.5-2 parts; thickener: 0.5-1.5 parts; stabilizer: 0.5-2 parts.

[0007] Preferably, the porous microspheres are poly-L-lactic acid composite porous hydroxyapatite microspheres with a particle size range of 10-100 microns and having an internal and external porous structure.

[0008] Preferably, the botulinum toxin is botulinum toxin type A, the gel matrix is ​​cross-linked hyaluronic acid, the buffer solution is a phosphate buffer solution with a pH value of 6.8-7.4, and the cross-linking agent is a combination of 1-ethyl-3-carbodiimide and N-hydroxysuccinimide.

[0009] Preferably, the thickener is sodium carboxymethyl cellulose, and the stabilizer is polyethylene glycol.

[0010] Preferably, a method for preparing a porous microsphere composite botulinum toxin gel comprises the following steps:

[0011] S1. Prepare raw materials: weigh the required weight portions of porous microspheres, botulinum toxin, gel matrix, buffer solution, crosslinking agent, thickener and stabilizer;

[0012] S2. Preparing porous microspheres: dissolving polylactic acid-glycolic acid copolymer in an organic solvent, and preparing porous microspheres by spray drying, wherein the spray drying conditions are: a feed rate of 5-15 mL / min, and an inlet air temperature of 100-150° C.;

[0013] Preparation of porous hydroxyapatite:

[0014] S201: preparing a hydroxyapatite suspension: preparing a hydroxyapatite aqueous solution with a mass concentration of 30%, placing it in a planetary ball mill for 20 minutes to obtain a hydroxyapatite suspension;

[0015] S202: preparing a 7% NH4HCO3 solution;

[0016] S203: adding the NH4HCO3 solution of step S02 to the hydroxyapatite suspension of step S01 at a mass ratio of 1:1, and stirring and mixing to obtain a mixed solution;

[0017] S204: subjecting the mixed solution obtained in step S03 to centrifugal spray drying and calcination to obtain hydroxyapatite porous microspheres;

[0018] S205: using a machine sieving method to collect microspheres within a target particle size range of 10-100 μm;

[0019] Finally, the two microspheres were mixed in a ratio of 1:1;

[0020] S3. Composite botulinum toxin: dissolve the botulinum toxin treated with freeze-dried protective agent in a buffer solution and add it to the porous microspheres for adsorption and composite reaction. The adsorption conditions are: temperature 2-6°C, time 10-14 hours;

[0021] S4, preparing gel: dissolving cross-linked hyaluronic acid in a buffer solution, adding porous microspheres compounded with botulinum toxin, and stirring evenly;

[0022] S5, cross-linking molding: adding a cross-linking agent, stirring evenly, and reacting for 2-4 hours to obtain a porous microsphere composite botulinum toxin gel;

[0023] S6, thickening and stabilization: add thickener and stabilizer, stir at low speed, and react for 1-2 hours;

[0024] S7. Purification and sterilization: The prepared gel is purified to remove unreacted residues and sterilized by filtration through a 0.20-0.24 micron filter to obtain the final product.

[0025] Preferably, in step S3, the lyoprotectant comprises a combination of sucrose and trehalose.

[0026] Preferably, between steps S4 and S5, the composite is treated with ultrasound, and the ultrasound conditions are: frequency of 18-22 kHz, power of 140-160 W, and treatment time of 8-12 minutes.

[0027] Preferably, in step S6, the stirring speed is controlled to be 100-200 rpm, and the stirring temperature is controlled to be room temperature 20-25°C.

[0028] The present invention provides a porous microsphere composite botulinum toxin gel and a preparation method thereof.

[0029] Beneficial effects:

[0030] 1. The present invention achieves a sustained-release effect of botulinum toxin by loading botulinum toxin on porous microspheres. The structural design of the porous microspheres enables the botulinum toxin to be slowly released over a long period of time, thereby extending the drug's action time and reducing the need for frequent injections.

[0031] 2. The present invention uses a lyoprotectant to treat botulinum toxin and composites it with porous microspheres, which effectively protects the biological activity of botulinum toxin. The ultrasonic treatment and cross-linking reaction in the preparation process also further improve the stability of botulinum toxin, ensuring its effectiveness during storage and use.

[0032] 3. The materials used in the present invention (such as porous microspheres and hyaluronic acid) have good biocompatibility, which reduces adverse reactions and inflammatory reactions caused by injection and improves the safety and applicability of the product.

[0033] 4. The present invention can customize the gel properties required in different application scenarios by adjusting the particle size of the porous microspheres, the degree of cross-linking of hyaluronic acid, and the viscosity of the gel. Such flexibility makes the preparation method applicable to various medical and cosmetic needs. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The present invention is a flow chart of a method for preparing a porous microsphere composite botulinum toxin gel. DETAILED DESCRIPTION

[0035] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] Please see attached Figure 1 The embodiment of the present invention provides a porous microsphere composite botulinum toxin gel, comprising the following components in parts by weight: porous microspheres: 5-15 parts; botulinum toxin: 0.1-1 parts; gel matrix: 70-90 parts; buffer solution: 5-10 parts; cross-linking agent: 0.5-2 parts; thickener: 0.5-1.5 parts; stabilizer: 0.5-2 parts.

[0037] Porous microspheres:

[0038] Poly-L-lactic acid composite porous hydroxyapatite microspheres (PLLA-porous HA microspheres) are a specially designed biocomposite material that combines the biodegradability of poly-L-lactic acid (PLLA) and the osteoconductivity of hydroxyapatite (HA). They are specifically designed in the form of microspheres with a porous structure. The development goal of this material is mainly to provide more efficient scaffold materials or drug delivery systems in bone tissue engineering and related medical applications.

[0039] Botulinum toxin:

[0040] Ingredients: Botulinum toxin type A

[0041] Effect: Botulinum toxin type A is a neurotoxin widely used in medical cosmetology and treatment of muscle spasms, etc. The botulinum toxin in the present invention is treated with a freeze-drying protective agent to maintain its biological activity and is compounded with porous microspheres to prolong its action time and effect.

[0042] Gel Matrix:

[0043] Material: Cross-linked Hyaluronic Acid (HA)

[0044] Function: Hyaluronic acid is a natural polysaccharide with excellent moisturizing and lubricating properties. Cross-linked hyaluronic acid improves its viscoelasticity and durability through cross-linking reaction, making it an ideal gel matrix.

[0045] Buffer solution:

[0046] Materials: Phosphate buffered saline (PBS)

[0047] Function: PBS is used to maintain the physiological stability of the gel and keep the pH value between 6.8-7.4, which helps to protect the activity of botulinum toxin and enhance the overall stability of the gel.

[0048] Crosslinking agent:

[0049] Materials: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS)

[0050] Function: The combination of EDC and NHS is used to enhance the cross-linking efficiency and stability of hyaluronic acid to form a stable gel structure.

[0051] Thickener:

[0052] Material: Sodium carboxymethyl cellulose (CMC-Na)

[0053] Function: CMC-Na is a water-soluble thickener that increases the viscosity and coating properties of the gel, making the gel more stable and easier to use.

[0054] Stabilizer:

[0055] Material: Polyethylene glycol (PEG)

[0056] Function: PEG acts as a stabilizer to improve the stability and sustained-release effect of botulinum toxin and prevent its degradation during storage and use.

[0057] The porous microspheres are poly-L-lactic acid composite porous hydroxyapatite microspheres with a particle size range of 10-100 microns and have an internal and external porous structure.

[0058] The botulinum toxin is botulinum toxin type A, the gel matrix is ​​cross-linked hyaluronic acid, the buffer solution is a phosphate buffer solution with a pH value of 6.8-7.4, and the cross-linking agent is a combination of 1-ethyl-3-carbodiimide and N-hydroxysuccinimide.

[0059] The thickener is sodium carboxymethyl cellulose and the stabilizer is polyethylene glycol.

[0060] A method for preparing a porous microsphere composite botulinum toxin gel comprises the following steps:

[0061] S1. Prepare raw materials: weigh the required weight portions of porous microspheres, botulinum toxin, gel matrix, buffer solution, crosslinking agent, thickener and stabilizer;

[0062] S2. Preparing porous microspheres: dissolving polylactic acid-glycolic acid copolymer in an organic solvent, and preparing porous microspheres by spray drying, wherein the spray drying conditions are: a feed rate of 5-15 mL / min, and an inlet air temperature of 100-150° C.;

[0063] Preparation of porous hydroxyapatite:

[0064] S201: preparing a hydroxyapatite suspension: preparing a hydroxyapatite aqueous solution with a mass concentration of 30%, placing it in a planetary ball mill for 20 minutes to obtain a hydroxyapatite suspension;

[0065] S202: preparing a 7% NH4HCO3 solution;

[0066] S203: adding the NH4HCO3 solution of step S02 to the hydroxyapatite suspension of step S01 at a mass ratio of 1:1, and stirring and mixing to obtain a mixed solution;

[0067] S204: subjecting the mixed solution obtained in step S03 to centrifugal spray drying and calcination to obtain hydroxyapatite porous microspheres;

[0068] S205: using a machine sieving method to collect microspheres within a target particle size range of 10-100 μm;

[0069] Finally, the two microspheres were mixed in a ratio of 1:1;

[0070] S3. Composite botulinum toxin: dissolve the botulinum toxin treated with freeze-dried protective agent in a buffer solution and add it to the porous microspheres for adsorption and composite reaction. The adsorption conditions are: temperature 2-6°C, time 10-14 hours;

[0071] S4, preparing gel: dissolving cross-linked hyaluronic acid in a buffer solution, adding porous microspheres compounded with botulinum toxin, and stirring evenly;

[0072] S5, cross-linking molding: adding a cross-linking agent, stirring evenly, and reacting for 2-4 hours to obtain a porous microsphere composite botulinum toxin gel;

[0073] S6, thickening and stabilization: add thickener and stabilizer, stir at low speed, and react for 1-2 hours;

[0074] S7. Purification and sterilization: The prepared gel is purified to remove unreacted residues and sterilized by filtration through a 0.20-0.24 micron filter to obtain the final product.

[0075] In step S3, the lyoprotectant includes a combination of sucrose and trehalose.

[0076] Lyoprotectant:

[0077] Ingredients: Combination of sucrose and trehalose

[0078] Function: Lyoprotectants are used to protect the biological activity of botulinum toxin during the freeze-drying and compounding process, ensuring the effectiveness of botulinum toxin after compounding with porous microspheres.

[0079] Between steps S4 and S5, the composite is treated with ultrasound, and the ultrasound conditions are: frequency of 18-22 kHz, power of 140-160 W, and treatment time of 8-12 minutes.

[0080] In step S6, the stirring speed is controlled to be 100-200 rpm, and the stirring temperature is controlled to be room temperature 20-25°C.

[0081] The following is an introduction in conjunction with specific embodiments:

[0082] Embodiment 1:

[0083] raw material:

[0084] Porous microspheres: 10 parts (particle size range 10-50 microns)

[0085] Botulinum toxin: 0.5 parts (botulinum toxin type A, treated with freeze-dried protective agent)

[0086] Gel base: 80 parts (cross-linked hyaluronic acid)

[0087] Buffer solution: 8 parts (PBS, pH 7.2)

[0088] Cross-linking agent: 1 part (combination of EDC and NHS)

[0089] Thickener: 1 part (CMC-Na)

[0090] Stabilizer: 1 part (PEG)

[0091] step:

[0092] S1: Weigh the required weight of each component.

[0093] S2: The porous microspheres were dissolved in dichloromethane and prepared by spray drying under the conditions of a feed rate of 10 mL / min and an inlet air temperature of 120 °C;

[0094] A 30% hydroxyapatite aqueous solution is prepared and ball-milled in a planetary ball mill to form a suspension, and then a 7% NH4HCO3 solution is prepared and added to the hydroxyapatite suspension at a mass ratio of 1:1 and mixed evenly, and then hydroxyapatite porous microspheres are prepared by centrifugal spray drying and calcination, and finally the target microspheres with a particle size range of 10-100 μm are collected by machine sieving;

[0095] Finally, the two microspheres were mixed in a ratio of 1:1.

[0096] S3: The botulinum toxin treated with lyoprotectant was dissolved in PBS and added to the porous microspheres for adsorption and complexing reaction at 4°C for 12 hours.

[0097] S4: Dissolve the cross-linked hyaluronic acid in PBS, add the porous microspheres complexed with botulinum toxin, and stir evenly.

[0098] S5: Add the combination of EDC and NHS, stir evenly, and react for 3 hours to obtain a porous microsphere-complexed botulinum toxin gel.

[0099] S6: Add CMC-Na and PEG, stir at low speed to ensure uniform distribution, and react for 1.5 hours.

[0100] S7: Purify the prepared gel and sterilize it by filtering it through a 0.22 micron filter to obtain the final product.

[0101] Embodiment 2:

[0102] raw material:

[0103] Porous microspheres: 8 parts (particle size range 20-70 microns)

[0104] Botulinum toxin: 0.3 parts (botulinum toxin type A, treated with freeze-dried protective agent)

[0105] Gel base: 75 parts (cross-linked hyaluronic acid)

[0106] Buffer solution: 10 parts (PBS, pH 7.0)

[0107] Cross-linking agent: 1.5 parts (combination of EDC and NHS)

[0108] Thickener: 0.7 parts (CMC-Na)

[0109] Stabilizer: 1.3 parts (PEG)

[0110] step:

[0111] S1: Weigh the required weight of each component.

[0112] S2: The porous microspheres were dissolved in ethyl acetate and prepared by spray drying under the conditions of a feed rate of 7 mL / min and an inlet air temperature of 110 °C;

[0113] A 30% hydroxyapatite aqueous solution is prepared and ball-milled in a planetary ball mill to form a suspension, and then a 7% NH4HCO3 solution is prepared and added to the hydroxyapatite suspension at a mass ratio of 1:1 and mixed evenly, and then hydroxyapatite porous microspheres are prepared by centrifugal spray drying and calcination, and finally the target microspheres with a particle size range of 10-100 μm are collected by machine sieving;

[0114] Finally, the two microspheres were mixed in a ratio of 1:1;

[0115] S3: The botulinum toxin treated with lyoprotectant was dissolved in PBS and added to the porous microspheres for adsorption and complexing reaction at 3°C ​​for 14 hours.

[0116] S4: Dissolve the cross-linked hyaluronic acid in PBS, add the porous microspheres complexed with botulinum toxin, and stir evenly.

[0117] S5: Add the combination of EDC and NHS, stir evenly, and react for 2 hours to obtain a porous microsphere-complexed botulinum toxin gel.

[0118] S6: Add CMC-Na and PEG, stir at low speed to ensure uniform distribution, and react for 2 hours.

[0119] S7: The prepared gel is purified and sterilized by filtration through a 0.24 micron filter to obtain the final product.

[0120] Embodiment 3:

[0121] raw material:

[0122] Porous microspheres: 12 parts (particle size range 30-100 microns)

[0123] Botulinum toxin: 0.8 parts (botulinum toxin type A, treated with freeze-dried protective agent)

[0124] Gel base: 85 parts (cross-linked hyaluronic acid)

[0125] Buffer solution: 5 parts (PBS, pH 7.4)

[0126] Cross-linking agent: 0.8 parts (combination of EDC and NHS)

[0127] Thickener: 1.2 parts (CMC-Na)

[0128] Stabilizer: 0.8 parts (PEG)

[0129] step:

[0130] S1: Weigh the required weight of each component.

[0131] S2: The porous microspheres were dissolved in acetonitrile and prepared by spray drying under the conditions of a feed rate of 12 mL / min and an inlet air temperature of 130 °C;

[0132] A 30% hydroxyapatite aqueous solution is prepared and ball-milled in a planetary ball mill to form a suspension, and then a 7% NH4HCO3 solution is prepared and added to the hydroxyapatite suspension at a mass ratio of 1:1 and mixed evenly, and then hydroxyapatite porous microspheres are prepared by centrifugal spray drying and calcination, and finally the target microspheres with a particle size range of 10-100 μm are collected by machine sieving;

[0133] Finally, the two microspheres were mixed in a ratio of 1:1.

[0134] S3: The botulinum toxin treated with lyoprotectant was dissolved in PBS and added to the porous microspheres for adsorption and complexing reaction at 5°C for 10 hours.

[0135] S4: Dissolve the cross-linked hyaluronic acid in PBS, add the porous microspheres complexed with botulinum toxin, and stir evenly.

[0136] S5: Add the combination of EDC and NHS, stir evenly, and react for 4 hours to obtain a porous microsphere-complexed botulinum toxin gel.

[0137] S6: Add CMC-Na and PEG, stir at low speed to ensure uniform distribution, and react for 1 hour.

[0138] S7: The prepared gel is purified and sterilized by filtration through a 0.20 micron filter to obtain the final product.

[0139] Table 1: Gel properties of porous microspheres composited with botulinum toxin in different embodiments

[0140]

[0141]

[0142] Among them, the table fields are explained as follows:

[0143] Product viscosity: refers to the thickness and fluidity of the gel. Higher viscosity means a thicker gel, lower viscosity means a thinner gel. Viscosity affects the coating properties and ease of use of the gel.

[0144] Product persistence: refers to how long a gel lasts in the skin or tissue. Products with high persistence can stay in the body longer, providing longer-lasting therapeutic or cosmetic effects.

[0145] Product sustained-release effect: refers to the release rate and control degree of botulinum toxin in the gel. Excellent sustained-release effect means that botulinum toxin can be released slowly and evenly, prolonging the efficacy and reducing side effects.

[0146] Biocompatibility: refers to the compatibility of the gel with biological tissues. High biocompatibility means that the gel will not cause obvious immune response or irritation when used in the body, and is highly safe.

[0147] Stability: refers to the ability of a gel to maintain its physical and chemical properties during storage and use. High stability means that the gel will not decompose, deteriorate or become ineffective over a long period of time.

[0148] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A porous microsphere-composite botulinum toxin gel, characterized in that: The invention comprises the following components in parts by weight: porous microspheres: 5-15 parts; botulinum toxin: 0.1-1 parts; Gel matrix: 70-90 parts; Buffer solution: 5-10 parts; Cross-linking agent: 0.5-2 parts; Thickener: 0.5-1.5 parts; Stabilizer: 0.5-2 parts.

2. The porous microsphere-composite botulinum toxin gel according to claim 1, characterized in that: The porous microspheres are poly-L-lactic acid composite porous hydroxyapatite microspheres with a particle size range of 10-100 microns and have an internal and external porous structure.

3. The porous microsphere-composite botulinum toxin gel according to claim 1, characterized in that: The botulinum toxin is botulinum toxin type A, the gel matrix is ​​cross-linked hyaluronic acid, the buffer solution is a phosphate buffer solution with a pH value of 6.8-7.4, and the cross-linking agent is a combination of 1-ethyl-3-carbodiimide and N-hydroxysuccinimide.

4. The porous microsphere-composite botulinum toxin gel according to claim 1, characterized in that: The thickener is sodium carboxymethyl cellulose, and the stabilizer is polyethylene glycol.

5. A method for preparing a porous microsphere-composite botulinum toxin gel, applied to a porous microsphere-composite botulinum toxin gel according to any one of claims 1 to 4, characterized in that: The following steps are involved: S1. Prepare raw materials: weigh the required weight portions of porous microspheres, botulinum toxin, gel matrix, buffer solution, crosslinking agent, thickener and stabilizer; S2. Preparing porous microspheres: dissolving polylactic acid-glycolic acid copolymer in an organic solvent, and preparing porous microspheres by spray drying, wherein the spray drying conditions are: a feed rate of 5-15 mL / min, and an inlet air temperature of 100-150° C.; Preparation of porous hydroxyapatite: S201: preparing a hydroxyapatite suspension: preparing a hydroxyapatite aqueous solution with a mass concentration of 30%, placing it in a planetary ball mill for 20 minutes to obtain a hydroxyapatite suspension; S202: preparing a 7% NH4HCO3 solution; S203: adding the NH4HCO3 solution of step S02 to the hydroxyapatite suspension of step S01 at a mass ratio of 1:1, and stirring and mixing to obtain a mixed solution; S204: subjecting the mixed solution obtained in step S03 to centrifugal spray drying and calcination to obtain hydroxyapatite porous microspheres; S205: using a machine sieving method to collect microspheres within a target particle size range of 10-100 μm; Finally, the two microspheres were mixed in a ratio of 1:1; S3. Composite botulinum toxin: dissolve the botulinum toxin treated with freeze-dried protective agent in a buffer solution and add it to the porous microspheres for adsorption and composite reaction. The adsorption conditions are: temperature 2-6°C, time 10-14 hours; S4, preparing gel: dissolving cross-linked hyaluronic acid in a buffer solution, adding porous microspheres compounded with botulinum toxin, and stirring evenly; S5, cross-linking molding: adding a cross-linking agent, stirring evenly, and reacting for 2-4 hours to obtain a porous microsphere composite botulinum toxin gel; S6, thickening and stabilization: add thickener and stabilizer, stir at low speed, and react for 1-2 hours; S7. Purification and sterilization: The prepared gel is purified to remove unreacted residues and sterilized by filtration through a 0.20-0.24 micron filter to obtain the final product.

6. The method for preparing a porous microsphere-composite botulinum toxin gel according to claim 5, characterized in that: In the step S3, the lyoprotectant includes a combination of sucrose and trehalose.

7. The method for preparing a porous microsphere-composite botulinum toxin gel according to claim 5, characterized in that: Between the steps S4 and S5, the composite is treated with ultrasound, and the ultrasound conditions are: frequency of 18-22 kHz, power of 140-160 W, and treatment time of 8-12 minutes.

8. The method for preparing a porous microsphere composite botulinum toxin gel according to claim 5, characterized in that: In step S6, the stirring speed is controlled to be 100-200 rpm, and the stirring temperature is controlled to be room temperature 20-25°C.

Citation Information

Patent Citations

  • Filling material for injection aesthetic surgery and preparation method of filling material

    CN108478865A

  • Human skin beautifying and wrinkle-removing filling agent and preparation method thereof

    CN113797389A

  • Microstructure preparation technology of botulinum toxin

    CN114630672A

  • Preparation method of biodegradable porous polymer scaffolds containing hydroxyapatite for tissue engineering

    KR100794174B1

  • Methods and compositions for microflillng the skin with hyaluronic acid using microchannel technology

    US20220257494A1

Cited By

  • Polylactic acid microsphere injection and preparation method thereof

    CN121401488A

  • Injection of polylactic acid microspheres and preparation method thereof

    CN121401488B